Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uncoupling protein 1 (UCP1), also known as thermogenin, is a specialized mitochondrial inner membrane protein exclusively found in brown and beige adipocytes. Its primary biological function is non-shivering thermogenesis, where it acts as a proton channel to dissipate the mitochondrial proton motive force as heat, effectively uncoupling substrate oxidation from ATP production. This process allows brown adipose tissue (BAT) to expend large amounts of energy, making UCP1 a high-priority target for treating metabolic disorders such as obesity and type 2 diabetes by increasing systemic caloric expenditure and improving glucose and lipid clearance. Therapeutic strategies focus on activating UCP1-mediated thermogenesis or inducing 'browning'—the recruitment of UCP1-positive beige cells within white adipose tissue. Pharmacological agents like beta-3 adrenergic agonists (e.g., mirabegron) and various nutraceuticals aim to stimulate the sympathetic-adipose axis to enhance UCP1 activity. However, drug development faces significant challenges in achieving tissue-specific activation to avoid cardiovascular side effects like hypertension and tachycardia, as well as the risk of systemic hyperthermia. While 'Brown adipose tissue function' is a physiological process rather than a single molecule, UCP1 is the definitive molecular effector and most specific therapeutic target associated with this phenomenon.
UCP1 facilitates a proton leak across the inner mitochondrial membrane, bypassing ATP synthase and dissipating the electrochemical gradient as heat instead of chemical energy (ATP). Drugs typically target UCP1 indirectly via beta-3 adrenergic receptor (ADRB3) activation, which stimulates cAMP/PKA signaling to release free fatty acids that both activate UCP1 protein and upregulate its gene expression.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uncoupling protein 1 (UCP1) (UCP1).